<DOC>
	<DOCNO>NCT02647866</DOCNO>
	<brief_summary>The purpose study determine safety tolerability administration multiple ascend dos KHK4083 select high dose tolerated subject moderately active Ulcerative Colitis ( UC ) follow Long-term Extension Therapy ( LTE ) phase eligible subject clinical response .</brief_summary>
	<brief_title>Study Monoclonal Antibody KHK4083 Moderate Ulcerative Colitis</brief_title>
	<detailed_description>A Phase 2 , double-blind clinical study multiple ascend dos KHK4083 ( placebo ) Long-term Extension Therapy ( LTE ) phase conduct approximately 60 randomized adult subject moderately active UC document unsuccessful previous treatment . The Treatment Period include double-blind Induction Therapy ( 12 week ) Open-label Therapy ( OLE ) phase phase ( 40 week ) eligible subject Week 12 . Subjects already enrol double-blind , long-term extension ( LTE ) precede version protocol worsen may eligible transition OLE Week 28 . The Follow Up Period last administration 16 week .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Colonic Diseases</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subject able willing comply study procedure , adhere dose , visit schedule followup procedure describe protocol ICF ; 2 . Subject voluntarily signs/dates Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve ICF accordance regulatory Institutional Guidelines ; 3 . Male female subject ≥ 18 year age time enrollment ; 4 . Subject UC diagnose least 6 month prior Screening visit ; 5 . Subject moderately active UC total Mayo score 49 endoscopic subscore least 2 , disease extends least 15 cm anal verge ; 6 . Subject previous treatment ( within 5 year prior Screening ) one following : corticosteroid , immunosuppressive medication TNF antagonist therapy unsuccessful lack efficacy response . 7 . Female subject ( WOCBP ) must negative pregnancy test Screening Baseline . WOCBP must agree use effective contraception ; 8 . Male subject ( include vasectomy ) must use adequate contraception study least 6 month last dose investigational product . 1 . Subject , , reason , judge Investigator inappropriate study ; 2 . Subject medical history clinically significant diseases/disorders ; 3 . Two biologic treatment different mechanism action ( e.g. , infliximab , vedolizumab golimumab ) Three antiTNF biologics e.g . infliximab , adalimumab 4 . Subject require prescription treatment UC , except stable , oral treatment UC 4 week prior screen . 5 . Subject receive follow prior treatment treatment within specified time prior Baseline visit : Natalizumab , efalizumab , rituximab lymphocytedepleting treatment , include limited , alkylating agent ( cyclophosphamide chlorambucil ) total lymphoid irradiation time ; TNF antagonists within 8 week , 5 halflives ( 12 week ) ; Vedolizumab within 16 week ; Methotrexate , cyclosporine , mycophenolate , tacrolimus , thalidomide , immune alter drug within 4 week ( ophthalmologic preparation permit ) ; 5ASA enema , steroid enema suppository use within 2 week ; and/or Investigational agent within 8 week 5 halflives ( whichever longer ) . 6 . Subject recent , suspect confirm symptomatic stenosis colon , abdominal abscess , ischemic colitis base clinical radiographic data ; history toxic megacolon ; previous surgery UC ; 7 . Subject know colonic dysplasia , adenomas polyposis ; 8 . Subject major surgery within 4 week prior Screening anticipate requirement major surgery ; 9 . Subject enteric pathogen ( include Clostridium difficile ) ; 10 . Subject follow hematological chemistry laboratory value : Platelet count &lt; 100,000/mm3 ; Neutrophils &lt; 1500/mm3 ; Serum creatinine ≥ 1.6 mg/dL ( ≥ 144.4 μmol/L ) ; Alkaline phosphatase &gt; 3 time upper limit normal ( ULN ) ; AST ALT &gt; 2 time ULN ; Total bilirubin &gt; 2 mg/dL , unless due Gilbert 's Syndrome ; Serum albumin &lt; 3 g/dL ; Hemoglobin &lt; 9 g/dL ; Glycated serum hemoglobin A1c ≥ 9 % . 11 . Subject clinically significant cardiac disease ; 12 . Subject pregnant breastfeeding ; 13 . Subject major immunologic reaction ; 14 . Subject Hepatitis B core antibody surface antigen positive and/or Hepatitis C antibody positive detectable RNA ; 15 . Subject history human immunodeficiency virus ( HIV ) positivity , test positive HIV , congenital acquire immunodeficiency ; 16 . Subject active TB , suspect extrapulmonary TB , history incompletely treat TB , latent TB latent infection . Subjects latent TB ( clinical finding , purify protein derivative [ PPD ] interferon gamma release assay [ IGRA ] ) may include study prophylactic therapy latent TB start least 4 week prior Screening . Subjects potentially untreated infection ( clinical finding ) exclude . 17 . Subject bacterial infection require treatment oral parenteral antibiotic , within 2 4 week , respectively . 18 . Subject history systemic opportunistic infection recurrent infection 19 . Subject malignancy history malignancy , except adequately treat basal cell skin cancer adequately treat carcinoma insitu cervix without recurrence least 5 year . 20 . Subject receive bacille CalmetteGuérin ( BCG ) vaccine within 6 month randomization live vaccination ( e.g. , measles , mumps , rubella [ MMR ] ; herpes zoster ; varicella , intranasal influenza ; oral poliomyelitis ) within 4 week randomization . 21 . Subject history active substance abuse . 22 . Subject severe acute chronic medical psychiatric condition laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>4083-002</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>UC</keyword>
	<keyword>Mayo Clinic Scoring</keyword>
	<keyword>Gastrointestinal Tract</keyword>
</DOC>